Association of a polymorphism in the monocyte chemoattractant protein-1/CCL2 gene and lupus nephritis in systemic lupus erythematosus patients. 2008

D Hoshi, and H Okamoto, and H Kaneko, and N Ichikawa, and C Terai, and H Yamanaka, and N Kamatani

UI MeSH Term Description Entries
D008181 Lupus Nephritis Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982). Glomerulonephritis, Lupus,Lupus Glomerulonephritis,Nephritis, Lupus,Glomerulonephritides, Lupus,Lupus Glomerulonephritides,Lupus Nephritides,Nephritides, Lupus
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016017 Odds Ratio The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases. Cross-Product Ratio,Risk Ratio,Relative Odds,Cross Product Ratio,Cross-Product Ratios,Odds Ratios,Odds, Relative,Ratio, Cross-Product,Ratio, Risk,Ratios, Cross-Product,Ratios, Risk,Risk Ratios
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults
D018932 Chemokine CCL2 A chemokine that is a chemoattractant for MONOCYTES and may also cause cellular activation of specific functions related to host defense. It is produced by LEUKOCYTES of both monocyte and lymphocyte lineage and by FIBROBLASTS during tissue injury. It has specificity for CCR2 RECEPTORS. Monocyte Chemoattractant Protein-1,Monocyte Chemotactic Protein-1,CCL2 Chemokine,Chemokine (C-C Motif) Ligand 2,Chemokines CCL2,Monocyte Chemotactic and Activating Factor,CCL2, Chemokine,CCL2, Chemokines,Chemoattractant Protein-1, Monocyte,Chemokine, CCL2,Chemotactic Protein-1, Monocyte,Monocyte Chemoattractant Protein 1,Monocyte Chemotactic Protein 1
D020022 Genetic Predisposition to Disease A latent susceptibility to disease at the genetic level, which may be activated under certain conditions. Genetic Predisposition,Genetic Susceptibility,Predisposition, Genetic,Susceptibility, Genetic,Genetic Predispositions,Genetic Susceptibilities,Predispositions, Genetic,Susceptibilities, Genetic

Related Publications

D Hoshi, and H Okamoto, and H Kaneko, and N Ichikawa, and C Terai, and H Yamanaka, and N Kamatani
October 2015, Human immunology,
D Hoshi, and H Okamoto, and H Kaneko, and N Ichikawa, and C Terai, and H Yamanaka, and N Kamatani
June 2004, Arthritis and rheumatism,
D Hoshi, and H Okamoto, and H Kaneko, and N Ichikawa, and C Terai, and H Yamanaka, and N Kamatani
October 2010, Molecular biology reports,
D Hoshi, and H Okamoto, and H Kaneko, and N Ichikawa, and C Terai, and H Yamanaka, and N Kamatani
April 2007, The Journal of rheumatology,
D Hoshi, and H Okamoto, and H Kaneko, and N Ichikawa, and C Terai, and H Yamanaka, and N Kamatani
August 2005, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
D Hoshi, and H Okamoto, and H Kaneko, and N Ichikawa, and C Terai, and H Yamanaka, and N Kamatani
October 2009, The Journal of rheumatology,
D Hoshi, and H Okamoto, and H Kaneko, and N Ichikawa, and C Terai, and H Yamanaka, and N Kamatani
April 2014, Nephrology (Carlton, Vic.),
D Hoshi, and H Okamoto, and H Kaneko, and N Ichikawa, and C Terai, and H Yamanaka, and N Kamatani
January 2019, Critical reviews in eukaryotic gene expression,
D Hoshi, and H Okamoto, and H Kaneko, and N Ichikawa, and C Terai, and H Yamanaka, and N Kamatani
June 2004, Seminars in cancer biology,
D Hoshi, and H Okamoto, and H Kaneko, and N Ichikawa, and C Terai, and H Yamanaka, and N Kamatani
June 2018, Rheumatology international,
Copied contents to your clipboard!